Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Journal of the American Geriatrics Society|August 31, 2007
Diagnosing and treating breast cancer in elderly women: a call for improved understandingLeona Downey, Robert Livingston, Alison Stopeck
Journal of Surgical Oncology|April 12, 2011
Systemic treatment of early breast cancer--a biological perspectiveSally Greenberg, Alison Stopeck, Hope S Rugo
The Oncologist|September 28, 2014
A pilot study of estradiol followed by exemestane for reversing endocrine resistance in postmenopausal women with hormone receptor-positive metastatic breast cancerPavani Chalasani, Alison Stopeck, Kathryn Clarke, et al.
BMJ Case Reports|January 9, 2016
Pathophysiology of tumour-induced microangiopathic haemolytic anaemiaPavani Chalasani, Jennifer M Segar, Marilyn Marron, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 25, 2020
Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitorsAlyssa Streff, Michele Chu-Pilli, Alison Stopeck, et al.
Biomicrofluidics|May 8, 2014
Isolation of viable cancer cells in antibody-functionalized microfluidic devicesXiangjun Zheng, Linan Jiang, Joyce Schroeder, et al.
Frontiers in Oncology|January 23, 2023
Case report: Metastatic metaplastic breast cancer with choriocarinomatous features: Targeting the choriocarcinoma component for cureKrisha K Mehta, Rosa Nouvini, Jingxuan Liu, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 21, 2015
Intravenous thiotepa for treatment of breast cancer-related leptomeningeal carcinomatosis: case seriesJaspreet Chahal, Alison Stopeck, Kathryn Clarke, et al.
The Oncologist|August 7, 2019
A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast CancerJennifer M Segar, Darien Reed, Alison Stopeck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2002
Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignanciesAlison Stopeck, Marrae Sheldon, Mahmood Vahedian, et al.
Pageof 4